Peginterferon alfa-2a Articles

Roche's Pegasys shows promise as a therapy for hepatitis B virus infections

14 July 2003

Roche to release a new drug each year in Japan

30 June 2003

Losses soar at Chugai on merger charge, underlying growth remains steady

2 June 2003

Chugai chief reviews pipeline, business prospects post Roche alliance

28 April 2003

Novartis grows stake in Roche, but merger still looks a long way off

3 February 2003

Roche undercuts rival with ribavirin brand

20 January 2003

Roche profits hit by weak foreign currency

19 August 2002

Roche stock performance begins to improve

22 July 2002

FDA grants Pegasys fast-track review

22 July 2002

Roche launches Pegasys in UK

15 July 2002

Global hepatitis market "set to reach $3.97 billion by 2007"

1 July 2002

Roche gets OKs for Pegasys, Copegus

1 July 2002

Somatropin OK for GH deficiency: UK NICE

3 June 2002

Roche pipeline set to deliver renewed momentum after 2004

6 May 2002

Roche's Pegasys: "unprecedented efficacy in hep C"

29 April 2002

Lower-than-expected sales for Roche in the first quarter of 2002

22 April 2002

Fillip for Roche as three drugs get EU backing

25 March 2002

Pegasys offers better QoL vs trad therapy

11 March 2002

Net income slides at Roche as it looks to sell off vitamins unit

4 March 2002

New NICE appraisal program goes for one-month consultation

25 February 2002

Analyst considers impact that loss of US Accutane patent will have on Roche

4 February 2002

Roche's "amicable" Rx price talks with Brazil

28 January 2002

Brazil govt drug price battle moves to hep C.

21 January 2002

Tally of NCEs in 2001 lends credence to talk of R&D productivity

21 January 2002

Roche and Chugai enter alliance with the Swiss firm the majority shareholder

10 December 2001

Long-term efficacy of Pegasys seen in HCV

15 November 2001

SciClone makes progress with Zadaxin in Japan

23 August 2001

Roche posts strong-than-expected results as pharma sales pick up

16 August 2001

Roche, S-P resolve peginterferon dispute

13 August 2001

Roche gets Swiss OK for Pegasys

8 August 2001

FDA approves Rebetol as separate treatment

31 July 2001

Anti-infective sales prospects in Latin American markets

23 July 2001

Roche licenses hep C drug from ICN

3 July 2001

Weston signs deal with Japanese firm

3 July 2001

Impact of US FDA's approval delays on drug majors and biotech: Lehman

29 June 2001

Inhale Therapeutics set to acquire Shearwater in $191 million deal

25 May 2001

Net income leaps 50% at Roche in 2000, but pharma sales disappoint

28 February 2001

Schering-Plough gets US approval for pegylated interferon alfa product

24 January 2001

Acquisitions to solve weak Roche pipeline?

15 January 2001

Schering-Plough and Roche reveal hep C data in bid to claim superiority

1 November 2000

Roche's R&D day offers "no surprises;"firm is still "richly-valued," says

31 October 2000

Enzon files suit against Roche over Pegasys

7 September 2000

Maxim and Roche link up in cancer and hep C

10 August 2000

Pegasys to get fast-track review in USA?

5 July 2000

World sale forecasts for antivirals to 2008

7 June 2000

Schering-Plough's PEGIntron gains first approval for hepatitis C

1 June 2000

Roche files for FDA approval of Pegasys, seeks prevention label for Tamiflu

25 May 2000

First pivotal results of Roche's Pegasys show sustained response

3 May 2000

Roche upbeat on pipeline despite problems with Trocade and Bonviva

13 April 2000

Roche wavers as more drugs suffer inlate-stage clinical trials

5 April 2000

Weston looking to raise L50 million

28 March 2000

Goldman Sachs analysts review prospects for Japanese pharmaceutical firms

14 December 1999

Roche predicts strong full-year sales as net income increases 15%

19 August 1999

New indication for Roferon-A approved in EU

24 June 1999

Bioject - one step ahead in a needle-free world

10 February 1999

Showing 101-155 of 155 articles

Go to beginningPreviousNextGo to end